Emerging Business Models in the Pharmaceutical Industries ...

Benchmarking - Top 20 Drugs by Sales
Rank Company Drug Revenues (Million US$)
1 Pfizer Lipitor $7,972
2 Merck Zocor $5,600
3 AstraZeneca Losec/Prilosec $4,623
4 Johnson n Johnson Procrit/Eprex $4,269
5 Pfizer Norvasc $3,846
6 GlaxoSmithKline Paxil $3,090
7 Pfizer Zoloft $2,742
8 GlaxoSmithKline Seretide/Advair $2,453
9 Pfizer Neurontin $2,269
10 Merck Cozaar/Hyzaar $2,200
11 Merck Fosamax $2,200
12 Bristol Myers Squibb Pravachol $2,173
13 Johnson n Johnson Risperdal $2,146
14 Bristol Myers Squibb Glucophage $2,049
15 AstraZeneca Nexium $1,978
16 Aventis Allegra $1,920
17 GlaxoSmithKline Augmentin $1,791
18 Pfizer Viagra $1,735
19 Merck Singulair $1,500
20 Aventis Lovenox $1,478
4%
Top 20 Drugs Rock Pharma Market
Though the block busters are shaky, the
top 20 selling drugs in 2003 will
contribute major revenues in the next few
years. They may be replaced by new
formulations supporting the semi block
buster model.
3%
3%
4%
3%3%3%3%
4%
4%
4%
4%
Top Selling Drugs
Source: JSB Intelligence
Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 48
4%
5%
5%
14%
7%
10%
7%
8%
Lipitor
Zocor
Losec/Prilosec
Procrit/Eprex
Norvasc
Paxil
Zoloft
Seretide/Advair
Neurontin
Cozaar/Hyzaar
Fosamax
Pravachol
Risperdal
Glucophage
Nexium
Allegra
Augmentin
Viagra
Singulair
Lovenox